Humacyte’s (HUMA) Buy Rating Reiterated at Benchmark

Benchmark restated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $15.00 target price on the stock.

A number of other equities research analysts also recently weighed in on the company. Cantor Fitzgerald restated an overweight rating and issued a $7.00 target price on shares of Humacyte in a research report on Tuesday, July 2nd. BTIG Research upped their target price on Humacyte from $8.00 to $11.00 and gave the stock a buy rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Humacyte currently has an average rating of Moderate Buy and an average target price of $8.60.

Humacyte Stock Performance

HUMA opened at $6.01 on Monday. The company has a market capitalization of $715.69 million, a price-to-earnings ratio of -6.01 and a beta of 1.52. The company has a debt-to-equity ratio of 0.61, a current ratio of 8.37 and a quick ratio of 8.37. Humacyte has a 1-year low of $1.96 and a 1-year high of $9.97. The business has a 50 day moving average price of $6.88 and a two-hundred day moving average price of $5.21.

Insider Transactions at Humacyte

In other news, CEO Laura E. Niklason sold 809,786 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $7.91, for a total transaction of $6,405,407.26. Following the completion of the sale, the chief executive officer now directly owns 5,381,354 shares of the company’s stock, valued at approximately $42,566,510.14. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Laura E. Niklason sold 809,786 shares of the stock in a transaction on Friday, May 31st. The stock was sold at an average price of $7.91, for a total value of $6,405,407.26. Following the completion of the sale, the chief executive officer now owns 5,381,354 shares in the company, valued at $42,566,510.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Heather Ledbetter Prichard sold 188,886 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.14, for a total value of $1,537,532.04. Following the completion of the sale, the chief operating officer now owns 2,625 shares of the company’s stock, valued at approximately $21,367.50. The disclosure for this sale can be found here. Insiders sold a total of 1,628,820 shares of company stock valued at $12,464,121 in the last three months. 23.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Humacyte

Several hedge funds and other institutional investors have recently modified their holdings of HUMA. Vanguard Group Inc. raised its holdings in shares of Humacyte by 28.7% during the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after acquiring an additional 896,415 shares in the last quarter. Renaissance Technologies LLC increased its position in Humacyte by 693.0% during the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after buying an additional 524,600 shares during the last quarter. Marshall Wace LLP increased its position in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after buying an additional 450,031 shares during the last quarter. Capstone Investment Advisors LLC acquired a new position in Humacyte during the first quarter worth $972,000. Finally, Private Advisor Group LLC increased its position in Humacyte by 232.7% during the first quarter. Private Advisor Group LLC now owns 317,624 shares of the company’s stock worth $988,000 after buying an additional 222,144 shares during the last quarter. 44.71% of the stock is currently owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.